{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:00:24Z","timestamp":1789837224038,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1007\/s11936-005-0015-1","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T09:29:12Z","timestamp":1180862952000},"page":"139-148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Beh\u00e7et\u2019s disease: Current therapeutic perspectives"],"prefix":"10.1007","volume":"7","author":[{"given":"Merav","family":"Leiba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ehrenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"15_CR1","first-page":"271","volume":"168","author":"B Adamantiades","year":"1931","unstructured":"Adamantiades B: Sur un cas d\u2019iritis a hypopyon recidivant. Ann d\u2019Oculist 1931, 168:271\u2013278.","journal-title":"Ann d\u2019Oculist"},{"key":"15_CR2","first-page":"1152","volume":"105","author":"H Beh\u00e7et","year":"1937","unstructured":"Beh\u00e7et H: \u00dcber rezidivierende aphthose durch ein Virus verursachte Geschw\u00fcre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937, 105:1152\u20131157.","journal-title":"Dermatol Wochenschr"},{"key":"15_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0049-0172(98)80001-2","volume":"27","author":"VG Kaklamani","year":"1998","unstructured":"Kaklamani VG, Vaiopoulos G, Kaklamanis PG: Behcet\u2019s disease. Semin Arthritis Rheum 1998, 27:197\u2013217.","journal-title":"Semin Arthritis Rheum"},{"key":"15_CR4","first-page":"2","volume":"1","author":"F Davatchi","year":"1997","unstructured":"Davatchi F, Shahram F, Akbarian M, et al.: Behcet\u2019s disease: analysis of 3443 cases. APLAR J Rheumatol 1997, 1:2\u20135.","journal-title":"APLAR J Rheumatol"},{"key":"15_CR5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3349\/ymj.1997.38.6.411","volume":"38","author":"CC Zouboulis","year":"1997","unstructured":"Zouboulis CC, K\u00f6tter I, Djawari D, et al.: Epidemiological features of Adamantiades-Behcet\u2019s disease in Germany and in Europe. Yonsei Med J 1997, 38:411\u2013422.","journal-title":"Yonsei Med J"},{"key":"15_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/00002281-200401000-00008","volume":"16","author":"S Yurdakul","year":"2004","unstructured":"Yurdakul S, Hamuryudan V, Yazici H: Behcet syndrome. Curr Opin Rheumatol 2004, 16:38\u201342. Most recent review on the current developments in Beh\u00e7et\u2019s disease.","journal-title":"Curr Opin Rheumatol"},{"key":"15_CR7","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1136\/ard.61.7.655","volume":"61","author":"I Kone-Paut","year":"2002","unstructured":"Kone-Paut I, Gorchakoff-Molinas A, Weschler B, et al.: Paediatric Behcet\u2019s disease in France. Ann Rheum Dis 2002, 61:655\u2013656.","journal-title":"Ann Rheum Dis"},{"key":"15_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1046\/j.1365-4362.2003.01741.x","volume":"42","author":"U Tursen","year":"2003","unstructured":"Tursen U, Gurler A, Boyvat A: Evaluation of clinical findings according to sex in 2313 Turkish patients with Behcet\u2019s disease. Int J Dermatol 2003, 42:346\u2013351.","journal-title":"Int J Dermatol"},{"key":"15_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1034\/j.1399-0039.2001.580202.x","volume":"58","author":"K Sano","year":"2001","unstructured":"Sano K, Yabuki K, Imagawa Y, et al.: The absence of disease-specific polymorphisms within the HLA-B51 gene that is the susceptible locus for Behcet\u2019s disease. Tissue Antigens 2001, 58:77\u201382.","journal-title":"Tissue Antigens"},{"key":"15_CR10","unstructured":"Criteria for diagnosis of Behcet\u2019s disease. International Study Group for Behcet\u2019s Disease [no authors listed]. Lancet 1990, 335:1078\u20131080."},{"key":"15_CR11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/003693308903400509","volume":"34","author":"AC Thompson","year":"1989","unstructured":"Thompson AC, Nolan A, Lamey PJ: Minor aphthous oral ulceration: a double-blind cross-over study of beclomethasone dipropionate aerosol spray. Scott Med J 1989, 34:531\u2013532.","journal-title":"Scott Med J"},{"key":"15_CR12","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","volume":"44","author":"S Yurdakul","year":"2001","unstructured":"Yurdakul S, Mat C, Tuzun Y, et al.: A double-blind trial of colchicine in Behcet\u2019s syndrome. Arthritis Rheum 2001, 44:2686\u20132692.","journal-title":"Arthritis Rheum"},{"key":"15_CR13","first-page":"92","volume":"5","author":"I Kotter","year":"1996","unstructured":"Kotter I, Durk H, Saal J, et al.: Therapy of Behcet\u2019s disease. Ger J Ophthalmol 1996, 5:92\u201397.","journal-title":"Ger J Ophthalmol"},{"key":"15_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1053\/sarh.2001.19819","volume":"30","author":"VG Kaklamani","year":"2001","unstructured":"Kaklamani VG, Kaklamanis PG: Treatment of Behcet\u2019s disease-an update. Semin Arthritis Rheum 2001, 30:299\u2013312.","journal-title":"Semin Arthritis Rheum"},{"key":"15_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/pmj.76.900.629","volume":"76","author":"V Kontogiannis","year":"2000","unstructured":"Kontogiannis V, Powell RJ: Behcet\u2019s disease. Postgrad Med J 2000, 76:629\u2013637.","journal-title":"Postgrad Med J"},{"key":"15_CR16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9394(14)72840-5","volume":"118","author":"SM Whitcup","year":"1994","unstructured":"Whitcup SM, Salvo Jr EC, Nussenblatt RB: Combined cyclosporine and corticosteroid therapy for sightthreatening uveitis in Behcet\u2019s disease. Am J Ophthalmol 1994, 118:39\u201345.","journal-title":"Am J Ophthalmol"},{"key":"15_CR17","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1093\/rheumatology\/38.12.1171","volume":"38","author":"CG Barnes","year":"1999","unstructured":"Barnes CG, Yazici H: Behcet\u2019s syndrome. Rheumatology 1999, 38:1171\u20131174.","journal-title":"Rheumatology"},{"key":"15_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/00002281-200101000-00004","volume":"13","author":"H Yazici","year":"2001","unstructured":"Yazici H, Yurdakul S, Hamuryudan V: Behcet disease. Curr Opin Rheumatol 2001, 13:18\u201322.","journal-title":"Curr Opin Rheumatol"},{"key":"15_CR19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","volume":"76","author":"Y Ozyazgan","year":"1992","unstructured":"Ozyazgan Y, Yurdakul S, Yazici H, et al.: Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet\u2019s syndrome: a single masked trial. Brit J Ophthalmol 1992, 76:241\u2013243.","journal-title":"Brit J Ophthalmol"},{"key":"15_CR20","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0161-6420(99)90156-2","volume":"106","author":"CML Sloper","year":"1999","unstructured":"Sloper CML, Powel RJ, Dua HS: Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999, 106:723\u2013728.","journal-title":"Ophthalmology"},{"key":"15_CR21","first-page":"569","volume-title":"Behcet\u2019s Disease: Basic and Clinical Aspects","author":"O Fain","year":"1991","unstructured":"Fain O, Houng Du LT, Wechsler B, et al.: Pulse cyclophosphamide in Behcet\u2019s disease. In Behcet\u2019s Disease: Basic and Clinical Aspects. Edited by O\u2019Duffy JD, KokmenE. New York: Marcel Dekker Publishing; 1991:569\u2013573."},{"key":"15_CR22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/BF03259272","volume":"3","author":"H Yazici","year":"1995","unstructured":"Yazici H, Yurdakul S, Hamuryudan V: Behcet\u2019s syndrome: how should we treat it?\n                           Clin Immunother 1995, 3:102\u2013107.","journal-title":"Clin Immunother"},{"key":"15_CR23","first-page":"635","volume-title":"Behcet\u2019s Disease","author":"F Shahram","year":"1993","unstructured":"Shahram F, Davatchi F, Chams H. et al.: Comparing 3 methods of cytotoxic therapy in ophthalmologic lesions of Behcet\u2019s disease. In Behcet\u2019s Disease. Edited by Wechsler B, Godeau P. Amsterdam: Excerpta Medica; 1993:635\u2013640."},{"key":"15_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"H Yazici","year":"1990","unstructured":"Yazici H, Pazarli H, Barnes CG, et al.: A controlled trial of azathioprine in Behcet\u2019s syndrome. N Engl J Med 1990, 322:281\u2013285.","journal-title":"N Engl J Med"},{"key":"15_CR25","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/art.1780400425","volume":"40","author":"V Hamuryudan","year":"1997","unstructured":"Hamuryudan V, Ozyazgan Y, Hizli N, et al.: Azathioprine in Behcet\u2019s syndrome: effects on long-term prognosis. Arthritis Rheum 1997, 40:769\u2013774.","journal-title":"Arthritis Rheum"},{"key":"15_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/0002-9343(84)90753-8","volume":"76","author":"JD O\u2019Duffy","year":"1984","unstructured":"O\u2019Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet\u2019s disease. Am J Med 1984, 76:75\u201384.","journal-title":"Am J Med"},{"key":"15_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJM199002013220509","volume":"322","author":"JD O\u2019Duffy","year":"1990","unstructured":"O\u2019Duffy JD: Behcet\u2019s syndrome. N Engl J Med 1990, 322:326\u2013328.","journal-title":"N Engl J Med"},{"key":"15_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0022-510X(98)00165-8","volume":"159","author":"S Hirohata","year":"1998","unstructured":"Hirohata S, Suda H, Hashimoto T: Low-dose weekly methotrexate for progressive neuropsychiatric manifestations of Behcet\u2019s disease. J Neurol Sci 1998, 159:181\u2013185.","journal-title":"J Neurol Sci"},{"key":"15_CR29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/0190-9622(91)70156-V","volume":"24","author":"JL Jorizzo","year":"1991","unstructured":"Jorizzo JL, White WL, Wise CM, et al.: Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behcet\u2019s disease. J Am Acad Dermatol 1991, 24:973\u2013978.","journal-title":"J Am Acad Dermatol"},{"key":"15_CR30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00041327-200106000-00011","volume":"21","author":"JC Nichols","year":"2001","unstructured":"Nichols JC, Ince A, Akduman L, et al.: Interferon-alpha 2a treatment of neuro-Behcet disease. J Neuroophthalmol 2001, 21:109\u2013111.","journal-title":"J Neuroophthalmol"},{"key":"15_CR31","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1001\/archderm.134.8.1010","volume":"134","author":"CC Zouboulis","year":"1998","unstructured":"Zouboulis CC, Orfanos CE: Treatment of Adamantiades-Behcet disease with systemic interferon alfa. Arch Dermatol 1998, 134:1010\u20131016.","journal-title":"Arch Dermatol"},{"key":"15_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archderm.138.4.467","volume":"138","author":"E Alpsoy","year":"2002","unstructured":"Alpsoy E, Durusoy C, Yilmaz E, et al.: Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002, 138:467\u2013471.","journal-title":"Arch Dermatol"},{"key":"15_CR33","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","volume":"128","author":"V Hamuryudan","year":"1998","unstructured":"Hamuryudan V, Mat C, Saip S. et al.: Thalidomide in the treatment of mucocutaneous lesions of the Behcet syndrome. A randomized double-blind, placebo-controlled trial. Ann Intern Med 1998, 128:443\u2013450.","journal-title":"Ann Intern Med"},{"key":"15_CR34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.7326\/0003-4819-128-6-199803150-00011","volume":"128","author":"G Ehrlich","year":"1998","unstructured":"Ehrlich G: Behcet disease and the emergence of thalidomide. Ann Intern Med 1998, 128:494\u2013495.","journal-title":"Ann Intern Med"},{"key":"15_CR35","doi-asserted-by":"crossref","first-page":"891","DOI":"10.7326\/0003-4819-124-10-199605150-00005","volume":"124","author":"K Yasui","year":"1996","unstructured":"Yasui K, Ohta K, Kobayashi M, et al.: Successful treatment of Behcet disease with pentoxifylline. Ann Intern Med 1996, 124:891\u2013893.","journal-title":"Ann Intern Med"},{"key":"15_CR36","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/ard.2003.014241","volume":"63","author":"M Leiba","year":"2004","unstructured":"Leiba M, Seligsohn U, Sidi Y, et al.: Thrombophilic factors are not the leading cause of thrombosis in Behcet\u2019s disease. Ann Rheum Dis 2004, 63:1445\u20131449. An extensive study showing that thrombophilia is not the cause of thrombosis in Beh\u00e7et\u2019s disease.","journal-title":"Ann Rheum Dis"},{"key":"15_CR37","first-page":"152","volume":"6","author":"SS Nitecki","year":"2004","unstructured":"Nitecki SS, Ofer A, Karram T, et al.: Abdominal aortic aneurysm in Behcet\u2019s disease: new treatment options for an old challenging problem. Isr Med Assoc J 2004, 6:152\u2013155.","journal-title":"Isr Med Assoc J"},{"key":"15_CR38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"358","author":"PP Sfikakis","year":"2001","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG, et al.: Effect of infliximab on sight-threatening panuveitis in Behcet\u2019s disease. Lancet 2001, 358:295\u2013296.","journal-title":"Lancet"},{"key":"15_CR39","first-page":"545","volume-title":"In Advances in Experimental Medicine and Biology","author":"KT Calamia","year":"2003","unstructured":"Calamia KT: Current and future use of anti-TNF agents in the treatment of autoimmune, inflammatory disorders. Adamantiades-Behcet\u2019s Disease. In In Advances in Experimental Medicine and Biology, vol 528. Edited by ZouboulisCC. New York: Kluwer Academic\/Plenum Publishers;2003:545\u2013549. A comprehensive summary of studies on the use of TNF inhibitors in Beh\u00e7et\u2019s disease."},{"key":"15_CR40","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S: Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet\u2019s disease with refractory uveoretinitis. J Rheumatol 2004, 31:1362\u20131368.","journal-title":"J Rheumatol"},{"key":"15_CR41","first-page":"S181","volume":"46","author":"M Melikoglu","year":"2002","unstructured":"Melikoglu M, Ozyazgan Y, Fersko I, et al.: The response of treatment resistant uveitis in Behcet\u2019s syndrome to a TNF-alpha blocker, etanercept: an open study. Arthritis Rheum Abst 2002, 46:S181.","journal-title":"Arthritis Rheum Abst"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-005-0015-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11936-005-0015-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-005-0015-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-005-0015-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:05:20Z","timestamp":1659092720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11936-005-0015-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["15"],"URL":"https:\/\/doi.org\/10.1007\/s11936-005-0015-1","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}